gp96-Ig-S
A candidate COVID-19 protein/peptide vaccine.
General information
gp96-Ig-S is a candidate COVID-19 vaccine. It contains glycoprotein 96 (a cellular heat shock chaperone) which is modified, so that its C-terminal endoplasmic reticulum retention sequence is exchanged for human IgG1 Fc, and thus, the fusion protein (gp96-Ig) is secreted. This fusion protein in complex with an antigenic viral peptide (produced in a different cell line) leads to antigen presentation eliciting immune response in the form of Spike protein-specific CD8+ and CD4+ T cells in epithelial tissues, including lungs and airways, as shown in mouse models (Fisher et al., 2021).
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Induction of SARS-CoV-2 Protein S-Specific CD8+ T Cells in the Lungs of gp96-Ig-S Vaccinated Mice
Protein factor Peptide Animal model In vitro Mixed substance |
in vitro binding assay; C57Bl/6 mice; human leukocyte antigen (HLA-A2.1) transgenic mice | 6.43 | The vaccine elicited immune responses in mouse models. Th1 CD8+ T cell response was observed in both lungs and spleen, whereas Th1 CD8+ T cell response was detected only in lungs. The Spike-specific CD8+ T cell IFNγ production in lungs in C57Bl/6 mice was lower compared to spleen (but similar in HLA-A2.1 mice), on the contrary, TNFα and IL-2 production in lungs was elevated. In the Spike-specific CD4+ T cells, IFNγ production was increased and IL-2 production decreased. The presence of specific factors suggests that lung tissue-resident memory T cell response was induced. |
Jan/26/2021 |
